Acurx Pharmaceuticals (ACXP) Competitors $0.35 +0.02 (+5.55%) Closing price 04:00 PM EasternExtended Trading$0.36 +0.01 (+2.97%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACXP vs. KZR, FGEN, RANI, GRCE, ALXO, PULM, COEP, SXTC, IPA, and MRNSShould you be buying Acurx Pharmaceuticals stock or one of its competitors? The main competitors of Acurx Pharmaceuticals include Kezar Life Sciences (KZR), FibroGen (FGEN), Rani Therapeutics (RANI), Grace Therapeutics (GRCE), ALX Oncology (ALXO), Pulmatrix (PULM), Coeptis Therapeutics (COEP), China SXT Pharmaceuticals (SXTC), ImmunoPrecise Antibodies (IPA), and Marinus Pharmaceuticals (MRNS). These companies are all part of the "pharmaceutical products" industry. Acurx Pharmaceuticals vs. Kezar Life Sciences FibroGen Rani Therapeutics Grace Therapeutics ALX Oncology Pulmatrix Coeptis Therapeutics China SXT Pharmaceuticals ImmunoPrecise Antibodies Marinus Pharmaceuticals Kezar Life Sciences (NASDAQ:KZR) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment, community ranking and earnings. Does the media prefer KZR or ACXP? In the previous week, Acurx Pharmaceuticals had 1 more articles in the media than Kezar Life Sciences. MarketBeat recorded 2 mentions for Acurx Pharmaceuticals and 1 mentions for Kezar Life Sciences. Kezar Life Sciences' average media sentiment score of 0.00 equaled Acurx Pharmaceuticals'average media sentiment score. Company Overall Sentiment Kezar Life Sciences Neutral Acurx Pharmaceuticals Neutral Which has higher earnings and valuation, KZR or ACXP? Acurx Pharmaceuticals has lower revenue, but higher earnings than Kezar Life Sciences. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKezar Life Sciences$7M4.88-$101.87M-$10.82-0.43Acurx PharmaceuticalsN/AN/A-$14.58M-$0.70-0.51 Does the MarketBeat Community prefer KZR or ACXP? Kezar Life Sciences received 120 more outperform votes than Acurx Pharmaceuticals when rated by MarketBeat users. However, 94.44% of users gave Acurx Pharmaceuticals an outperform vote while only 57.08% of users gave Kezar Life Sciences an outperform vote. CompanyUnderperformOutperformKezar Life SciencesOutperform Votes13757.08% Underperform Votes10342.92% Acurx PharmaceuticalsOutperform Votes1794.44% Underperform Votes15.56% Do insiders and institutionals hold more shares of KZR or ACXP? 67.9% of Kezar Life Sciences shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 10.4% of Kezar Life Sciences shares are held by insiders. Comparatively, 26.0% of Acurx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more risk and volatility, KZR or ACXP? Kezar Life Sciences has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, Acurx Pharmaceuticals has a beta of -1.38, suggesting that its share price is 238% less volatile than the S&P 500. Do analysts prefer KZR or ACXP? Kezar Life Sciences presently has a consensus price target of $39.50, suggesting a potential upside of 744.02%. Acurx Pharmaceuticals has a consensus price target of $8.00, suggesting a potential upside of 2,163.08%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than Kezar Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kezar Life Sciences 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Acurx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is KZR or ACXP more profitable? Kezar Life Sciences' return on equity of -54.95% beat Acurx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Kezar Life SciencesN/A -54.95% -46.11% Acurx Pharmaceuticals N/A -392.36%-223.78% SummaryAcurx Pharmaceuticals beats Kezar Life Sciences on 8 of the 14 factors compared between the two stocks. Get Acurx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACXP vs. The Competition Export to ExcelMetricAcurx PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.30M$6.83B$5.57B$8.67BDividend YieldN/A2.50%5.27%4.19%P/E Ratio-0.328.7927.2020.17Price / SalesN/A263.51412.92161.90Price / CashN/A65.8538.2534.64Price / Book1.046.677.114.72Net Income-$14.58M$143.49M$3.23B$247.80M7 Day Performance1.58%6.34%4.61%3.36%1 Month Performance-2.46%15.43%13.35%9.71%1 Year Performance-85.27%6.87%31.75%14.41% Acurx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACXPAcurx Pharmaceuticals1.7254 of 5 stars$0.35+5.6%$8.00+2,163.1%-86.0%$8.30MN/A-0.323News CoveragePositive NewsHigh Trading VolumeKZRKezar Life Sciences4.2625 of 5 stars$4.45+1.1%$39.50+787.6%-35.0%$32.51M$7M-0.3460FGENFibroGen4.1662 of 5 stars$0.32+2.0%$10.00+3,029.9%-71.0%$32.28M$7.00M-0.26570News CoverageRANIRani Therapeutics1.7449 of 5 stars$0.57+2.5%$9.40+1,537.3%-86.9%$32.19M$1.20M-0.54110Negative NewsGap UpGRCEGrace Therapeutics2.6779 of 5 stars$3.16+6.4%$12.00+279.7%N/A$32.04MN/A-2.72N/AHigh Trading VolumeALXOALX Oncology2.646 of 5 stars$0.58-0.1%$3.30+470.2%-93.6%$30.90MN/A-0.1940Analyst RevisionPULMPulmatrix0.2373 of 5 stars$8.44-5.1%N/A+328.4%$30.81M$1.92M-3.2020COEPCoeptis Therapeutics0.672 of 5 stars$8.75-2.2%N/A+55.7%$30.75M$62,874.00-1.512SXTCChina SXT Pharmaceuticals0.5743 of 5 stars$1.94-7.2%N/A-78.6%$30.71M$1.82M0.0090IPAImmunoPrecise Antibodies2.5711 of 5 stars$0.67-0.4%$4.00+497.2%-32.3%$30.65M$24.00M-0.8680Gap UpMRNSMarinus Pharmaceuticals2.022 of 5 stars$0.55-0.2%$4.79+771.6%-63.9%$30.32M$30.99M-0.22110News Coverage Related Companies and Tools Related Companies Kezar Life Sciences Alternatives FibroGen Alternatives Rani Therapeutics Alternatives Grace Therapeutics Alternatives ALX Oncology Alternatives Pulmatrix Alternatives Coeptis Therapeutics Alternatives China SXT Pharmaceuticals Alternatives ImmunoPrecise Antibodies Alternatives Marinus Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACXP) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGet Ready for Elon Musk’s BIGGEST Comeback YetTesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored50-year legend: Here’s exact day stocks will crashGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acurx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
